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Abstract 
In the brain, serotonin (5-hydroxytryptamine, 5-HT) controls a multitude of physiological 
and behavioral functions. Serotonergic neurons in the raphe nuclei give rise to a complex 
and extensive network of axonal projections throughout the whole brain. A major challenge 
in the analysis of these circuits is to understand how the serotonergic networks are linked 
to the numerous functions of this neurotransmitter. In the past, many studies employed 
approaches to inactivate different genes involved in serotonergic neuron formation, 5-HT 
transmission or metabolism. Although these approaches have contributed significantly to 
our understanding of serotonergic circuits, they usually result in life-long gene inactivation. 
As a consequence compensatory changes in serotonergic and other neurotransmitter 
systems may occur and complicate the interpretation of the observed phenotypes. To 
dissect the complexity of the serotonergic system with greater precision, approaches to 
reversibly manipulate subpopulations of serotonergic neurons are required. In this review, 
we summarize findings on genetic animal models that enable control of 5-HT neuronal 
activity or mapping of the serotonergic system. This includes a comparative analysis of 
several mouse and rat lines expressing Cre or Flp recombinases under Tph2, Sert, or Pet1 
promoters with a focus on specificity and recombination efficiency. We further introduce 
applications for Cre-mediated cell-type specific gene expression to optimize spatial and 
temporal precision for the manipulation of serotonergic neurons. Finally, we discuss other 
temporally regulated systems, such as optogenetics and DREADD approaches to control 
5-HT neuron activity. 
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  1. Introduction  
 
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine that acts as a neurotransmitter in 
the central nervous system (CNS) and as an autacoid in the periphery. Serotonin 
synthesis in the CNS is restricted to serotonergic neurons, which originate from the raphe 
nuclei of the brain stem and extend vast axonal projections into different areas of the brain 
and spinal cord. Its synthesis is a two-step reaction. Tryptophan hydroxylase (TPH) 2 
catalyzes the first, rate-limiting step in the CNS, in contrast to TPH1, which is active in the 
periphery.1-3 Tph2 is expressed exclusively in serotonergic neurons within the brain and in 
the enteric nervous system in the gut but not in other peripheral organs or neuronal cell 
types.2-6 Serotonin packaging into vesicles is mediated by vesicular monoamine 
transporter (VMAT) 2, which is expressed in monoaminergic neurons.7 Serotonin actions 
are mediated by its numerous receptors, that have different expression patterns within the 
CNS, including presynaptic locations.8, 9 For example, 5-HT1A autoreceptors, which are 
expressed on soma and dendrites of serotonergic neurons, mediate inhibition of cell 
firing.10 Another important component of serotonergic neurons is serotonin transporter 
(SERT), which mediates 5-HT uptake.11 In the brain of adult animals, SERT is mainly 
expressed on 5-HT producing neurons of the raphe nuclei and astrocytes.12 During 
development, transient SERT expression in the brain is broader and includes 
nonserotonergic neurons in limbic, thalamic and retinal areas.13 Furthermore, SERT is 
located in a number of peripheral cells, such as platelets, adrenomedullary chromaffin 
cells, crypt cells in the gut, lung, liver, and testis.14, 15 SERT expression is therefore not 
restricted to serotonergic neurons. 
Serotonergic neurons of the raphe nuclei are organized in groups, which are distinguished 
by their different anatomical location, axonal trajectories and physiological properties.16-18 
The more rostrally located serotonergic cell groups, B6-B9, project to forebrain regions, 
whereas caudal serotonergic groups, B1-B5, project towards the spinal cord and brain 
stem.19 Although anatomically clustered, groups of serotonergic neurons are not 
homogenous in their electrophysiological properties and consist of different 
subpopulations, which are not fully characterized so far.20, 21 
During brain development, serotonergic neurons arise from distinct units of the neural 
tube, named rhombomeres (r1-r3 and r5-r7).19 Developing 5-HT neuronal precursors along 
the rhombomeres express the PC12 ETS domain-containing transcription factor 1 (Pet1) 
and LIM homeobox transcription factor 1 (Lmx1b) which are involved in serotonergic 
neuron differentiation. Lmx1b precedes Pet1 expression, and is also expressed in 
dopaminergic progenitors and neurons.22 Pet1 was thought to be a specific marker of 
differentiated post-mitotic serotonergic neurons.16, 23-25 However, more recent studies 
indicated that Pet1 is also active in some non-serotonergic cells in adult and developing 
brain and in peripheral organs such as adrenal glands, the 5-HT-synthesizing 
enterochromaffin cells of the intestine, developing kidney, and pancreas.26, 27  
The fact that development of serotonergic neurons, 5-HT synthesis, release and reuptake 
require expression of multiple specific genes was used for the analysis of serotonergic 
circuits. Mouse models were engineered to express different reporters specifically in 
serotonergic neurons, such as the transgenic ePet-EYFP28, the TPH2-GFP knock-in,29 and 
the TPH2-LacZ knock-in mouse lines.30 These models have been employed in various in 
vivo and in vitro studies to examine electrophysiological properties and morphology of 5-
HT neurons.28-30 To manipulate the serotonergic system, various strategies for 
enhancement or inhibition of neuronal activity have been used. Besides numerous 
pharmacological interventions, a number of studies employed genetic approaches to 
inactivate or overexpress different genes involved in serotonergic neuron formation, 5-HT 
transmission and metabolism.31-38 The behavior and physiological consequences of life-
long alterations in serotonergic signaling in the brain in these models were recently 
reviewed.39-42 
The characterization of these genetic models contributed greatly to our understanding of 
serotonergic circuits. However, genetic approaches which result in life-long changes in 
gene expression (for example full knockouts or constitutive overexpression models) may 
induce compensatory mechanisms in other neurotransmitter systems, thus making it 
impossible to assess 5-HT function per se. Moreover, these models do not provide an 
opportunity to study functions of specific subpopulations of 5-HT neurons. In this review 
we summarize new tools which provide higher specificity and temporal control to study 
serotonergic circuitry. 
 
2. Targeted expression of Cre and Flp recombinases in 
serotonergic cells 
 
To manipulate serotonergic neurons in the CNS of mice, many studies have made use of 
the standard Cre-LoxP approach for cell type-specific recombination. The Cre protein is a 
site-specific DNA recombinase, that catalyses the recombination between two 34 bp long 
loxP sequences.43, 44 Cre-dependent recombination in conjunction with LoxP-flanked target 
genes or stop cassettes can inactivate or activate the expression of a gene of interest 
(GOI) respectively. Over the last decade, a number of transgenic and knock-in Cre-
expressing mouse lines have been generated. To direct transgene expression with the 
same developmental timing and spatial expression patterns as certain endogenous genes, 
bacterial artificial chromosomes (BACs) have also been widely used.45 BACs are DNA 
constructs, which are capable to host the DNA fragments of >350 kilobase pairs with a 
high degree of stability.46, 47 Therefore, they are suitable for inserting large promoter 
regions including distant regulatory elements to drive Cre expression in specific cell 
populations.48, 49 Alternatively, knock-in approaches can be applied to control expression of 
the recombinase using the same machinery which controls expression of cell specific 
genes. In these cases the expression pattern is much more accurate and does not require 
time-consuming isolation and characterization of the promoter.50 Most importantly, the 
knocked-in transgene does not generate additional mutations at an unknown locus as 
classical randomly integrated transgenes do. Of note, during the knock-in approach one 
allele of the gene in which Cre is inserted will be disrupted leading to a heterozygous 
knockout of this gene unless the transgene is linked via a 2A-peptide sequence at the 3’-
end of the endogenous driver gene. For some genes, such as Tph2, the heterozygosity 
does not evoke behavioral alterations51, whereas for other genes, e.g., Sert, the deletion of 
one allele results in changes in neurochemistry and physiology (see below 2.1.1) and 
should be considered as an additional factor to be controlled for. Once a specific Cre line 
is successfully generated, the expression of recombinase can be functionally 
characterized by crossbreeding with Cre-dependent reporter strains, such as Rosa26loxP-
STOP-lacZ or ROSA26loxP-stop-EYFP.52, 53 which start to express β-Galactosidase (β-
Gal) or EYFP, respectively, once Cre recombinase is active. Co-localization analysis of 
reporter expression and serotonergic markers is an important step in evaluating the 
specificity and confirming the efficiency of Cre-dependent recombination. In case of 
inducible Cre-ERT2 models, a chimeric protein consisting of a codon-optimized Cre 
recombinase fused to a triple mutant form of the human estrogen receptor (ERT2) is 
expressed in targeted cells. The mutant receptors no longer bind endogenous estradiol, 
but instead recognize the synthetic ligand Tamoxifen (TMX). Upon TMX administration, the 
recombinase gains access to the nuclear compartment and initiates recombination,54 
thereby permitting temporal control of gene manipulation.  
Another enzyme, flippase (Flp), which works similar to Cre and mediates DNA 
recombination between 34bp-long Flp recognition target (FRT) sites, has also been used 
in such approaches (reviewed in55). Available Cre and Flp transgenic mouse lines for the 
serotonergic system are summarized in Table 1, and discussed below in more detail. 
 
2.1. Cre recombinase expression driven by the Sert promoter 
 
2.1.1. Knock-in SERT-Cre 
Among the first published lines targeting specific neurotransmitter systems is the SERT-
Cre mouse line, generated by knocking in Cre into the Slc6A4 locus (gene coding for 
SERT) by the group of R. Hen.50 In the raphe, 99% of cells which underwent 
recombination were TPH-positive, and nearly all serotonergic neurons were recombined. 
These results indicate a high recombination efficiency and specificity in the raphe of this 
SERT-Cre mouse line. This line has been widely used for different applications, including 
studies of heart development, effects of selective serotonin re-uptake inhibitors (SSRIs), 
sudden infant death syndrome, depression, addiction, development, and metabolism.56-60. 
For example, Narboux-Nême and colleagues disabled serotonergic transmission by 
crossing SERT-Cre to VMAT2fl/fl mice which led to a major (~95%) depletion of central 5-
HT, but not other monoamines, through excision of the VMAT2 in SERT-positive cells.61 
However, this SERT-Cre line has several limitations. Firstly, due to the disruption of the 
Slc6A4 this SERT-Cre mouse represents a heterozygous knockout resulting in a mild 
behavioral and biochemical phenotype50 and therefore, proper controls (optimally SERT-
Cre+ GOIfl/fl versus SERT-Cre+ GOIwt/wt) should be used in experiments. Another limitation 
of this line is Cre recombination occuring in non-serotonergic neurons of the thalamus, the 
cingulate cortex, and the CA3 region of the hippocampus (summarized in the Table1) due 
to transient SERT expression in these regions during early development.62 Furthermore, 
the SERT-Cre line is prone to germ-line transmission of the recombined allele, due to 
SERT-driven Cre expression in male germ cells.59 This may lead to the generation of a 
total, instead of a cell-type specific, knockout. By crossing SERT-Cre and ObRbfl/fl mice the 
group of G. Karsenty inactivated the leptin receptor b (LepRb) in serotonergic neurons.30 
Based on the experiments performed in these mice they postulated that leptin regulation of 
appetite occurs by inhibition of 5-HT synthesis in the brain. However, a detailed analysis 
by other group could not confirm the expression of LepRb in serotonergic neurons and it 
was supposed that the phenotypes, observed by Karsenty group were most probably 
resulting from total instead of conditional LepRb knockout59.  
 
2.1.2. BAC-SERT-Cre 
Three BAC-SERT-Cre transgenic mouse lines were generated in frames of GENSAT 
project (http://www.gensat.org/index.html).49 In 2 founder lines (E33/E35) Cre expression 
was restricted to adult serotonergic neurons, whereas in the third line (E124) Cre 
expression was also observed in corticothalamic and thalamocortical neurons.49, 63 
Moreover, in the E33 and E124 lines of BAC-SERT-Cre mice, Cre expression was 
observed in the developing visual system64 and the upper layers of the barrel cortex,65 
respectively. These findings confirm SERT expression by non-serotonergic neurons during 
development, as shown earlier.13, 62 Taken together, BAC-SERT-driven Cre expression 
targets all serotonergic neurons, however, ectopic SERT expression during development 
and developmental recombination in transgenic SERT-Cre lines must be considered.  
 
2.2. Recombinase expression driven by the Pet1 promoter 
 
2.2.1. ePet1-Cre 
Using a 40kb-long DNA region upstream of the Pet1 gene containing an enhancer 
essential for proper Pet1 expression, the laboratory of E. Deneris generated an ePet1-Cre 
line which enables Cre-mediated recombination restricted to all 5-HT neurons.28 Within the 
CNS, no ePet activity was detected outside the serotonergic system, however the analysis 
of LacZ expression in the periphery of R26RePet-Cre mice revealed Cre-dependent 
recombination in some cells of skin, gut, pancreas, and cardiac neural crest. 
2.2.2. ePet-Flpe 
A Flp recombinase driver line, ePet-Flpe, was generated in the laboratory of S. Dymecki66 
with the same ePet construct used by the Deneris’ group previously to generate the ePet-
Cre line.28 In the raphe of ePet-Flpe mice, the activity of Flp is high and mediates 
recombination in most 5-HT raphe neurons.66 
2.2.3. Pet1210-Cre 
To control somatic recombination in the Pet1 lineage more reliably, the group of M. 
Pasqualetti generated mice expressing Cre under control of a large 210kb-long fragment 
of the Pet1 genetic locus, including all putative regulatory regions.26 Pet1210-Cre transgenic 
mice revealed the existence of non-serotonergic neuronal populations, which express Pet1 
within the raphe, mostly in the B8 and B9 cell groups. Cre expression was also detected in 
embryonic kidney and pancreas, demonstrating that Pet1210-Cre mice are useful to study 
rather Pet-1 expressing lineages other than 5-HT neurons in particular (Table 1). Based on 
these findings, the specificity of other Pet-1 driven Cre lines and reporters, such as ePet1-
EYFP,28 should be reevaluated in these non-serotonergic neuronal populations and 
peripheral tissues. 
2.2.4. BAC-Pet1-Cre 
Another BAC-based Pet1-Cre mouse line was generated by the group of Y.Q. Ding67 by 
insertion of the Cre coding sequence into the Pet1 locus. After crossing with Rosa26 
reporter mice, X-Gal staining and double immunostaining for Cre and 5-HT revealed raphe 
nuclei-specific Cre expression.  
The efficiency of Cre recombination was assessed by breeding Pet1-Cre mice with carriers 
of a floxed Lmx1b gene. In the resulting mice, 5-HT and SERT were almost absent in the 
whole brain, except for a single 5-HT-positive neuron found in the dorsal raphe (DR) (1%). 
It was thereby shown that adult Lmx1bPet1-Cre mice lack essentially all 5-HT neurons and 
terminals. The HPLC measurements still revealed the presence of residual 5-HT, although 
at concentrations 10 fold lower than in wild type animals. It is unclear whether this is due to 
undetected serotonergic neurons that did not undergo recombination or the HPLC results 
reflect contamination by blood 5-HT due to insufficient perfusion with saline before tissue 
isolation. Information about non-serotonergic Cre expression was not provided for this line. 
2.2.5. BAC-Pet1-CreERT2 
The same group also generated a BAC-Pet1-CreERT2 transgenic mouse line that allows 
TMX-inducible recombination.68 In this model, recombination was shown to be specific for 
serotonergic neurons in the DR and raphe magnus (RM), but only 85% of TPH2 
expressing neurons co-expressed the floxed reporter gene after TMX treatment. 
Crossbreeding of this Pet1-CreERT2 line with Lmx1bfl/fl mice led to 40% reductions in brain 
5-HT levels and downregulation of serotonergic markers.68 
One limitation of this mouse line is its FVB/N background used for the generation of 
founder lines. Most floxed mice are generated on a C57BL/6 background, which has 
become the most widely used strain for developmental and behavioral studies. The FVB/N 
line was reported to have higher than C57BL/6 mouse line locomotor activity, anxiety, and 
basal body temperature and is homozygous for the Pde6brd1 allele, causing retinal 
degradation (http://jaxmice.jax.org/strain/001800.html). As a consequence, most FVB/N 
mice are blind69 and thus, not suitable for behavioral experiments. This phenotype might 
also be inherited after crossing the Pet1-CreERT2 line to other strains and might have an 
unpredictable impact on experimental results.  
 
2.3. Cre recombinase expression driven by the Tph2 promoter 
 
2.3.1. BAC-TPH2-CreERT2 
After discovery of the brain specific TPH isoform6 the Tph2 promoter was used to direct 
Cre expression selectively to 5-HT neurons. In 2009, the group of D. Bartsch applied a 
BAC-based transgenic approach to create TMX-inducible TPH2-CreERT2 mice.70 Besides 
higher specificity of the Tph2 promoter for serotonergic neurons in comparison to SERT or 
Pet1, use of CreERT2 in this line allows recombination at any stage of development or 
adulthood. The same BAC-based construct was also later used to generate a TPH2-
CreERT2 rat line.71 High specificity of Cre expression upon TMX treatment was 
demonstrated in both TPH2-CreERT2 mouse and rat lines. However, rats showed a lower 
recombination efficacy compared to mice (77% in rats vs. 90% in mice) (Table 1).  
2.3.2. BAC-TPH2-CreERT2 
A comparable TPH2-CreERT2 mouse line, based on a BAC construct, was also generated 
by Yadav and colleagues72 to study leptin-dependent 5-HT control of appetite. 
Characterization of this line after breeding with Rosa26loxP-STOP-lacZ mice52 and TMX 
treatment revealed β-Gal staining in DR, median raphe (MnR), and caudal raphe (CR) 
nuclei of the brainstem but not in hypothalamic or other regions. The specificity for 
serotonergic neurons within these areas has not been determined however.  
2.3.3. BAC-TPH2-iCreERT2 
A similar mouse line (TPH2-iCreERT2) was independently generated by B. Gloss, 
(http://jaxmice.jax.org/strain/016584.html). However in this case, an improved version of 
Cre gene (iCre) was employed by applying mammalian codon usage and by lowering the 
high CpG content of the prokaryotic coding sequence, thereby reducing the chances of 
epigenetic silencing in mammals.73, 74 
We have confirmed iCreERT2-mediated recombination within the DR, but not in the other 
brain regions using crossbreeding of this mouse line to Rosa26loxP-STOP-lacZ,52 
ROSA26loxP-stop-EYFP,53 and Rosa26loxP-STOP-tdTomato (Jackson Laboratories, 
B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J Stock Number: 007914) reporter mice 
(Fig.1 A, B, C). Moreover, injection of an adeno associated virus (AAV), EF1a-DIO-CheTA-
EYFP, into the medial DR indicated effective Cre-mediated recombination in TPH2-
iCreERT2 mice (Fig.1D). However, a more detailed analysis of the specificity and efficacy 
of Cre expression in this line is still pending. 
 
In summary, a wide repertoire of genetic tools to target Cre-mediated recombination to 
serotonergic neurons is now available (Table 1). Pet1-Cre and SERT-Cre lines are well 
characterized and represent useful tools to study the serotonergic system, whereby Sert-
driven Cre lines have higher specificity and recombination efficiency than Pet1-driven 
transgenes, as recently demonstrated in the comparative study of VMATSert-Cre and 
VMATPet1-Cre mice.75 However, both promoters are not exclusively selective for the 
serotonergic lineage, whereas Tph2-driven Cre expression represents a more specific tool 
and should be regarded as a better model to target 5-HT-producing neurons specifically in 
the future. Additionally, the recent availability of the Tph2-driven rat Cre line71 allowed 
researchers to apply the more sophisticated behavioral tests for higher cognitive functions 
that have been already developed for use in rats, but not in mice. 
3. Targeting defined serotonergic subpopulations  
As described in the sections above, precise targeting of a transgene to most serotonergic 
neurons can be performed successfully using several different mouse lines, albeit with 
some limitations. However, the serotonergic system itself is heterogeneous and includes 
various subpopulations of neurons with different connectivity, functions, and 
developmental origins. Manipulating these subpopulations selectively requires more 
advanced methods.  
3.1 Dual recombinase strategies 
Making use of newly developed genetic technologies, the group of S. Dymecki, identified 
rhombomere (r)-defined 5-HT sublineages that differ in gene expression with respect to 
progenitor and precursor cells.66 These investigators have created a novel dual 
recombinase-responsive indicator allele, RC-Fela, and a Flpe recombinase driver line, 
ePet-Flpe. While RC-Fela serves as recombination reporter, ePet-Flpe directs 
recombination to Pet1-expressing 5-HT precursors. Combining RC-Fela with ePet-Flpe 
and Cre lines, specific for particular rhombomeres, enables isolation and manipulation of 
specific 5-HT neuronal subpopulations arising from these rhombomeres. For example, 
En1-Cre mice expressing Cre under the engrailed 1 (En1) promoter were used to study 
the subpopulation of 5-HT neurons originating from r1. In a comparable approach, the 
intersectional alleles RC-FrePe and RC-FPDi were used to identify 5-HT neurons 
mediating breathing reflex control.76 These triple transgenic animals provide new tools for 
in vivo manipulation of specific 5-HT subpopulations and for “functional mapping” studies. 
In another study using the same selective dual recombinase strategy, Kim and colleagues 
directed tetanus toxin light chain (tox) synthesis to serotonergic subpopulations and 
thereby inhibited vesicular neurotransmission in those neurons.77 By recombinase 
expression under Pet-1 and En1 promoters in En1-Cre, ePet1-Flpe, RC-PFtox mice, they 
targeted the subpopulation of Pet1-descendant 5-HT neurons arising from serotonergic 
progenitors in r1. Tox action was thereby restricted to cells expressing both Cre and Flpe 
recombinases and required two recombination events. Using the described dual-
recombinase technique, higher specificity (targeting of individual serotonergic subgroups) 
was achieved when compared to single-recombinase or conventional transgenic 
methodologies.  
 
3.2. Viral mediated gene transfer 
An alternative to transgenic approaches is virus-mediated gene transfer into specific brain 
structures. Spatial control of vector delivery can be achieved by using the appropriate 
stereotaxic injection coordinates. 
Adenoviruses were among the first viruses to be successfully used for the specific 
infection of DR.78 In this approach, stereotaxic injection of a Cre-expressing adenovirus 
(AdCre)79 into the DR of a Cre-dependent LacZ reporter mouse line CAG-LoxP-stop-
LacZ80 led to the expression of Cre recombinase in approximately 12% of serotonergic 
neurons. Within 9 days after the injection, 43% of Cre-expressing 5-HT neurons were also 
positive for LacZ, confirming the validity of the method to target Cre-recombination 
throughout the DR. 
Lentiviruses have also been applied to label serotonergic neurons. To drive the expression 
of the EGFP exclusively in serotonergic neurons, an optimized Tph2 promoter with a two-
step transcriptional amplification design was employed.81 Stereotactic injections of such 
viruses to medulla oblongata covering some of the midline and ventral raphe led to EGFP 
expression that was 97% colocalized with TPH expression. Of particular importance is the 
ability of lentiviruses to stably integrate into the genome of non-dividing cells, which is 
useful for lineage tracing. 
Meanwhile more advanced techniques combining AAV and transgenic approaches have 
been developed to enable highly selective transgene expression. For example, by injecting 
a double-floxed AAV with an inverse open reading frame for a channelrhodopsin2-
mCherry fusion protein (AAV2 DIO ChR2-mCherry) into the raphe obscurus (RO) of ePet-
Cre mice, DePuy and colleagues showed that roughly half of 5-HT neurons in the raphe 
area were infected and 97% of infected cells were serotonergic.82 Recently, sindbis virus, 
canine adenovirus serotype 2 (CAV2), and rabies viruses have been developed for 
anterograde, retrograde, and transsynaptic retrograde transport, respectively, and used to 
study serotonergic circuitry.83-90 
 
3.2.1. Anterograde transport 
Suzuki et al. injected a GFP-tagged sindbis virus into the DR for anterograde tracing of 
single serotonergic neurons to the olfactory bulb.87 The advantage of using sindbis virus is 
its high transfection efficiency in the CNS and its capacity to carry large amounts of 
genetic material. However, this virus is suitable only for acute in vivo work as infected 
neurons start degenerating 7 days after viral injection.91 
 
3.2.2. Retrograde transport 
For retrograde tracing studies, Wu et al. injected retrogradely transported CAV2-Cre virus 
into the Nucleus tractus solitarii (NTS) of conditional TPH2lox/lox mice.90 Upon transport 
from the injection site to the cell bodies, Cre inactivates the Tph2 gene, specifically in 
neurons with projections to the injected area. TPH2 staining was decreased in RO and RM 
serotonergic neurons by 60-80%, while DR neurons were unaffected. As a result, 5-HT 
levels in the NTS of injected TPH2lox/lox mice were decreased by about 75%. In 
combination with ablation of specific neuropeptide-expressing neurons, this study allowed 
elucidation of the serotonergic mechanisms of feeding and body weight regulation.90  
Interestingly, many AAVs, though not all, show a robust capacity for retrograde infection 
and subsequent transgene expression in mice. To isolate neuromodulatory serotonergic 
neurons that send axons to the basolateral amygdala (BLA), Rothermel et al.85 used 
recombinant, pseudotyped AAVs (rAAVs) engineered to improve transduction efficiency 
and tissue tropism using capsid genes from other AAV serotypes (e.g., AAV2/1). The 
applied virus carried a Cre-dependent expression switch (2/9.DIO.ChR2-EYFP) to allow 
ChR2-EYFP expression only in Cre-positive cells. Stereotaxic injection into the BLA of 
SERT-Cre mice resulted in ChR2-EYFP expression in a number of raphe neurons, mainly 
in the DR. 
 
3.2.3. Transsynaptic transport 
To analyze monosynaptic inputs to DR and MnR serotonergic neurons, Ogawa and 
colleagues used a retrograde transsynaptic system based on a modified rabies virus that 
initially infects only cognate receptor (TVA protein) expressing cells and lacks a 
glycoprotein required for transsynaptic spread.83 SERT-Cre mice50 were injected with two 
helper viruses expressing the glycoprotein and TVA after Cre recombination into either DR 
or MnR.88 This allowed the virus to spread transsynaptically to cells with direct synaptic 
contact to DR or MnR serotonergic neurons. Here, 95.8 % of infected TVA expressing 
cells were shown to be serotonergic and 30.5 % of 5-HT neurons were infected and 
expressed TVA. A small number of neighboring 5-HT-containing neurons were targeted as 
well.83 A rabies virus tracing strategy in SERT-Cre mice was also used in other studies to 
generate a whole-brain atlas of putative monosynaptic inputs onto forebrain-projecting DR 
and MnR serotonergic neurons or to characterize the distinct excitatory, inhibitory, and 
peptidergic inputs to the DR.84, 86, 89 However, released rabies virus can be taken up by 
adjacent terminals that may or may not be synaptically connected.92 Classification of 
connectivity patterns will permit further functional dissection of the serotonergic system 
and enable analysis of the physiological relevance of specific input circuits. 
Taken together, viral delivery entails some disadvantages in comparison to transgenic 
animals such as postoperative recovery, limited injection volumes, and challenges 
associated with injection accuracy. Moreover, adeno93-97 and sindbis91 viruses might evoke 
immune responses and inflammation. The regular serotypes (1-10) of AAV cause minimal 
in vivo immune response,98 but some may cause gliosis99 and neurological deficits. 
Lentiviruses are more conservative in this respect and pose less of a risk of CNS damage. 
As an advantage viruses permit much higher expression levels of transgenes and enable 
retrograde transport enabling labeling and manipulation of neuronal subpopulations 
defined by their axonal terminals. Furthermore, viral mediated transgene expression 
represents a useful tool to deliver light-sensitive proteins for optogenetic approaches (see 
below). Though conventional viral vectors cannot incorporate very large transcriptional 
control units similar to BACs, they are optimal for the delivery of small transgenes such as 
Cre recombinase or Cre-dependent expression cassettes. Due to the ease and low cost of 
viral production in comparison to transgenic animals, viral methodology allows facile 
implementation of new genetic tools into experimental designs. 
4. Temporal control of gene expression within the 
serotonergic system 
 
4.1. Inducible Cre-expressing mouse lines  
Performing a genetic manipulation at a selected time point during the lifetime allows the 
study of age-specific biochemical and behavioral effects within the serotonergic system. 
Several inducible Cre lines that enable excision or activation of genes at chosen time 
points within the serotonergic system are described in the sections above49, 68, 70, 71, 100 and 
are summarized in Table 1. However, these are not without limitations. Recombination 
mediated by Cre or other recombinases is an irreversible and relatively slow process. 
Furthermore, repeated TMX injections are necessary to permit drug delivery to all 
serotonergic neurons and to induce appropriate recombination rates. While TMX is FDA 
(U.S. Food and Drug Administration) approved, administration at doses higher than 150 
mg/kg has been shown to evoke toxic effects in mice.101, 102 Moreover, it should be taken 
into account that TMX is a strong estrogen receptor antagonist. Therefore, minimal doses 
of TMX should be used. Moreover, recent studies demonstrated that systemic activation of 
CreERT2 might elicit hematological toxicity.101, 102 Therefore, use of proper controls, such 
as Cre+GOIwt/wt + TMX is essential.  
 
4.2 Tetracycline-sensitive systems 
Audero et al. suppressed serotonergic firing by overexpressing 5-HT1A autoreceptors 
reversibly in transgenic mice,103 using the tetracycline-Off (tet-Off) system.104, 105 Double 
transgenic mice were generated by breeding mice carrying the tet-promoter (Ptet) inserted 
upstream of the endogenous 5-HT1A receptor gene (5-Htr1atetO allele) with mice encoding 
the tetracycline transactivator (tTA) inserted downstream the ATG codon of the 
endogenous Slc6A4 (gene coding for SERT). tTA is an artificial transcription factor, that 
binds to Ptet, which in turn, mediates the overexpression of a GOI, in this case the 5-
Htr1a. Administration of Doxycycline (Dox, a stable tetracycline analogue) in this model 
leads to the prevention of transactivation of 5-HT1A receptors and, therefore, allows 
temporal control of their expression. Although 5-HT specificity is based on the Sert 
promoter, which might be also active in non-serotonergic cells, 5-HT1A receptor 
overexpression in double-transgenic animals is restricted to raphe nuclei of the mid- and 
hindbrain. However, it has not been determined whether the affected cells are all 
serotonergic. 
Weber et al. designed a comparable ON/OFF system for genetic manipulations in 5-HT 
neurons.106 Similar to Audero and colleagues, they generated double-transgenic mice 
encoding tTA under the Tph2 promoter and a nLacZ reporter under the control of the-tet-
response system (TPH2-tTA/Ptet-nLacZ mice). Dual-label fluorescence 
immunohistochemistry identified LacZ expressing cells as serotonergic. Extraserotonergic 
brain regions were largely devoid of X-Gal staining, except for sparse β-Gal activity in the 
hypothalamus and beneath the aqueduct. Additionally, in the raphe, a few TPH2-negative 
cells were β-Gal positive, revealing some nonspecific gene targeting. Dox administration 
completely suppressed Ptet-mediated reporter expression and subsequent Dox withdrawal 
resulted in reactivation.  
When 5-HT-specific tTA mice are mated with Ptet-Cre/loxP-flanked target gene animals, 
spatially controlled, inducible gene deletion (TPH2-tTA/Ptet-Cre/loxP) can be achieved, 
comparable to TMX-inducible CreERT2 systems. In addition to the spatial control by the 
chosen promoter, temporal control of gene expression is possible with the described tet-
Off methodologies. Unlike the Cre/loxP system, gene manipulations are reversible. 
However, Ptet-controlled gene expression after Dox withdrawal occurs with a delay, 
depending on the animal’s age, Dox concentration, duration of treatment, and many other 
factors that have to be controlled for. In contrast to i.p. administration of TMX, Dox 
treatment is more suitable for behavior studies as it can be added to the drinking water 
diminishing effect of stress. Since Dox has a bitter taste, sugar or sweeteners are often 
added to Dox solutions that may lead to an increase in drinking volume, additional body 
weight gain, or other unexpected behavioral outcomes.  
 
4.3 DREADDs 
A different method for efficient modulation of signal transduction in selected neurons is the 
introduction of Designer Receptors Exclusively Activated by Designer Drugs (DREADD) – 
engineered G-protein-coupled receptors that are activated by otherwise inert synthetic 
ligands. During recent years, several modifications of this technique have been used for in 
vitro and in vivo experiments.107-109 The example below made use of a Gi-DREADD (Di), a 
synthetic Gi/o-protein–coupled receptor that activates inwardly rectifying potassium 
channels upon stimulation with the compound clozapine-N-oxide (CNO) resulting in 
hyperpolarization and transient neuronal silencing.110  
To study the influence of serotonergic activity on homeostatic control, Di was expressed 
via previously described dual-recombinase methodology with cell-subtype precision.66, 77, 
109 A combination of the single recombinase-responsive allele RC-PDi, responsive to Cre, 
with SERT-Cre was used to express Di in nearly all serotonergic neurons. These cells 
responded to CNO with hyperpolarization that led to the suppression of cell excitability. 
Furthermore, incorporation of a Cre-inducible reporter allele, RC-rePe, allowed 
visualization of Di expressing cells by GFP. Beyond serotonergic neurons, a population of 
extraserotonergic neurons in the thalamus was shown to express Di as well, due to 
presence of SERT-positive cells in this brain region. Current-clamp membrane potential 
recordings from cultured serotonergic neurons of the lower brainstem revealed a ~40 % 
reversible reduction in firing rates in Di expressing neurons after CNO exposure. 
Administration of CNO to transgenic animals resulted in rapid attenuation of chemoreflex, 
as well as a decrease in core body temperature representing vital physiological functions 
of 5-HT.109 DREADDs enable ligand-inducible inhibition of SERT-expressing neurons that 
is reversible within hours, and serves as model for functional mapping of neurons. CNO-
mediated inhibition happens within a shorter time frame as compared to Dox- or TMX-
inducible systems. At the same time, inertness of CNO has been questioned by others due 
to its redox partners and their biological effects.111 If CNO is not effectively eliminated by 
the kidneys, it can be reduced to the tertiary amine clozapine in vivo.112, 113 Various tertiary 
amine reduction routes generate compounds that efficiently act as agonists for DREADDs 
and a number of other receptors. In turn, receptor-mediated intracellular signaling 
pathways may be activated and impact animal physiology.114 These other possible actions 
of CNO metabolites are capable of reducing designer receptor–based cell and effect 
specificity and should be excluded by the use of appropriate controls. As another word of 
caution, all G-protein coupled receptors when artificially expressed at high levels are able 
to produce downstream coupling events without ligand presence. Various groups, 
including ourselves have observed this with DREADDs (S. Kasparov, unpublished 
observations). Therefore, it is critical to control for changes in cellular biochemistry or 
physiology in animals expressing DREADDs before CNO application.  
4.4. Optogenetics 
Optogenetics is another current technique to modulate neuronal function that does not 
involve chemical ligands and enables much higher temporal resolution.115 Optogenetics 
enables researchers to manipulate firing rates of specific neuronal populations and to 
measure the outcome using physiological and behavioral readouts in vivo. For tight optical 
control of neuronal excitability, light-sensitive channels or light-driven ion pumps are 
expressed in genetically defined neurons. The most commonly used optogenetic actuator 
is the non-selective cation channel channelrhodopsin, ChR2, and its derivatives. Using 
BAC technology, Zhao and colleagues generated a mouse line expressing ChR2 driven by 
the Tph2 promoter, TPH2-ChR2-EYFP.116 Co-localization of the reporter EYFP with 5-HT 
was shown for serotonergic neurons in the DR (116 and Fig.2A). Transgene expression 
was moderate in MnR and DR as approximately 15% of TPH2-positive cells were EYFP-
negative.116 Electrophysiological recordings from the EYFP-positive neurons showed 
responsiveness to blue light. It is important to stress that ChR2 and similar proteins have 
to be expressed in the target cells at fairly high levels to enable efficient control of 
excitability. We employed this mouse model to study the impact of descending 5-HT-ergic 
control on sensory transmission in the spinal cord, based on previous studies that revealed 
a dual role for 5-HT in inhibition and facilitation of nociceptive input.117-120 These earlier 
studies relied mainly on gross lesions, broadly acting pharmacological manipulations, and 
electrical stimulation of the DR, techniques with obvious limitations such as compensatory 
re-wiring of the pathways, impact on the release of other neuromodulators,121, 122 and co-
activation of non-5-HT neurons and fibres of passage.123 In theory, optogenetic stimulation 
of DR 5-HT neurons should help to overcome these limitations.124 In anaesthetized TPH2-
ChR-EYFP mice, optogenetic stimulation of 5-HT neurons in dorsolateral DR (coordinates 
from lambda: 0.3 mm ML, -1 mm AP, -3.4 mm DV; blue light stimulation: 10 msec ON, 10 
msec OFF, 20 sec, 20 mV) did not significantly alter the expression of c-Fos, a marker of 
neuronal excitability,125 in the dorsal horn of the spinal cord (Fig. 2B), which serves as an 
index of the nociceptive input.126 Despite the refinement of the targeting techniques to 
specifically excite DR 5-HT neurons, the impact of serotonergic innervation of the spinal 
cord on nociceptive transmission remains ambiguous. Our negative finding might also 
indicate that different 5-HT subpopulations (that we could have stimulated simultaneously) 
have opposing effects on the nociceptive control so as to cancel each other out.  
To refine the spatial specificity, mouse lines expressing Cre recombinase under cell-
specific promoters, in combination with viral delivery can also be used for optogenetic 
experiments. Such an approach was used in the study by Dugue et al., where viral vectors 
were injected into transgenic SERT-Cre mice (described above).127 In this study, response 
thresholds in awake behaving SERT-Cre mice following injection of viruses carrying Cre-
dependent ChR2-EYFP into the DR (coordinates from bregma: 0 mm ML, 4.4 to -4.7 mm 
AP, -2.8 to -2.9 mm DV, with a 340 caudal angle) were higher compared to control mice in 
the von Frey assay, a simple test of mechanosensitivity.128 The work of Dugue et al.127 and 
our studies (Fig. 2B-D) show that the response might differ between anesthetized and 
conscious animals, and that the roles of different serotonergic subpopulations may not be 
identical. 
Delivery of light-sensitive channels is possible by combining the above described mouse 
lines expressing Cre under cell-type specific promoters with recently developed mouse 
lines expressing various opsins in a Cre-dependent manner.129 However, due to the 
heterogeneity of the serotonergic system, this will not allow precise targeting of particular 
subpopulations of 5-HT neurons.  
Finally, since rat transgenics are much less developed, injection of viral vectors with 
optogenetic actuators (either direct targeting with Tph2 promoter130 or a combination of 
TPH2-Cre with a Cre-dependent vector) may be used in this species. 
In any case, using blue light for activation of optogenetic constructs requires careful 
controls for the effects of temperature and blue light itself. For example, we recently 
reported that blue light induces activation-like signals in functional magnetic resonance 
imaging experiments probably due to the local heating.131 Control for the effects of blue 
light has become a particular issue since the recent demonstration of the vasomotor 
effects mediated by melanopsin in peripheral blood vessels.132 Development of more 
sensitive optogenetic tools that can be activated by application of low intensity light133-136 
will help to overcome these concerns.  
 
The techniques discussed in this section allow manipulations of specific neuronal 
populations in freely behaving animals with improved spatial and temporal precision. 
Optogenetics and DREADDs both involve the introduction of non-native proteins into 
neurons that thereby respond to defined stimuli (light or CNO) with altered excitability. For 
the analysis of temporal dynamics of specific circuits, optogenetics must be used, whereby 
an optical fiber needs to be implanted and manipulations can only affect the illuminated 
area in the brain. In contrast, by a simple systemic CNO administration all DREADDs 
distributed within large tissue volumes can be stimulated simultaneously. Likewise, the tet-
Off system allows gene expression control in all tissues expressing the chosen promotor. 
In all cases, unknown side effects of chemical agent administration or blue light have to be 
considered.101, 102, 131, 132, 137-139 
 
Summary 
Serotonergic neurons in the raphe nuclei give rise to a complex and extensive network of 
axonal projections throughout the whole brain. A major challenge in the analysis of these 
circuits is to understand how the serotonergic networks are linked to the numerous 
functions of this neurotransmitter. Several new methodologies to manipulate 
subpopulations of serotonergic neurons and to control 5-HT neuron activity have been 
developed during recent years, including the generation of different serotonergic-neuron-
specific Cre lines, the invention of a dual recombination strategy, effective tools for 
temporal control of gene expression, DREADDs, and optogenetics. The nature of the 
experimental question dictates which option should be chosen as each has different merits 
and limitations. Importantly, since none of the described systems is totally free of 
nonspecific effects. For the most accurate and informative interpretation of results, 
adequate controls should be incorporated into experimental designs. Nonetheless, these 
new tools and methods, alone and in combination, enable powerful new routes to 
investigate the serotonin system. 
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5-HT - 5-hydroxytryptamine  
AAV - Adeno associated viral vector 
BAC - Bacterial artificial chromosome 
BLA - Basolateral amygdala 
CAV2 - canine adenovirus serotype 2  
ChR2 - Channelrhodopsin 2 
CNO - Clozapine-N-oxide 
CNS - Central nervous system 
CR - Caudal raphe 
Di - Synthetic Gi/o-protein coupled receptor (DREADD) 
Dox - Doxycycline 
DR - Dorsal raphe  
DREADD - Designer Receptors Exclusively Activated by Designer Drugs 
En1 - Engrailed 1 
Flp – Flippase 
GOI - Gene of interest 
IHC - Immunohistochemistry 
LacZ - Gene coding for β-galactosidase 
Lmx1b - LIM homeobox transcription factor 1 
NTS - Nucleus tractus solitarii 
MnR - Median raphe 
ObRb - Leptin receptor b 
LepRb - Leptin receptor b  
Pet1 - PC12 ETS domain-containing transcription factor 1 
Ptet - Tet-promoter 
r - Rhombomere 
RM - Raphe magnus 
RO - Raphe obscurus 
SERT - Serotonin transporter 
SSRI - Serotonin reuptake inhibitor 
Tet - Tetracyclin 
TMX - Tamoxifen 
Tox - Tetanus toxin light chain 
TPH2 - Tryptophan hydroxylase 2 
tTA - tetracycline transactivator  
VMAT - Vesicular monoamine transporter 
β-Gal - β-galactosidase 
DT - Diphteria toxin 
TVA protein - Cognate receptor 
 Figure legends 
Figure 1. Cre-mediated recombination in the TPH2-iCreERT2 mouse. A. LacZ 
expression in the raphe nuclei of the TPH2-iCreERT2 x R26R double transgenic mouse. 
DR – dorsal raphe nucleus, MnR – median raphe nuclei, CR – caudal raphe nuclei. B. 
EYFP expression (immunohistochemistry with anti-GFP antibody) in the dorsal raphe 
nuclei of the TPH2-iCreERT2 x ROSA26loxP-stop-EYFP double transgenic mouse. C. 
Expression of tdTomato in the raphe of TPH2-iCreERT2 x Rosa26loxP-STOP-tdTomato 
reporter mice. Arrowhead indicates neuronal cell bodies, arrow -indicates neuronal 
processes. D. EYFP expression (immunohistochemistry with anti-GFP antibody) in the 
dorsal raphe nuclei of the TPH2-iCreERT2 mouse injected with AAV virus (EF1a-DIO-
CheTA-EYFP).  
In all experiments Cre expression was induced by 3 consecutive TMX injections (120 
mg/kg for A, B and C, and 100 mg/kg for D) on days 1, 3, and 5. Mice were sacrificed on 
day 12-15. 
Figure 2. TPH2-ChR2-EYFP mouse as a model for the study of serotonergic 
circuitry. A. Specificity of EYFP expression controlled by Tph2 promoter: 
immunohistochemical analysis with anti-5-HT antibodies in dorsal raphe nuclei in TPH2-
ChR2 mouse (10x (left panel) and 40x (right panel) magnification. Neuronal activation in 
lamina I/II of the dorsal horn of the spinal cord was investigated through analysis of c-Fos 
expression (as previously described in 112) following application of a series of noxious 
pinch stimuli (pneumatic pincher: 2.5 N x 3) of the left hindpaw in control and TPH2-ChR2-
EYFP mice during optogenetic stimulation (10 msec ON, 10 msec OFF, 20 sec, 20 mV) in 
the dorsolateral dorsal raphe nucleus (coordinates from lambda: 0.3 mm ML, -1 mm AP, -
3.4 mm DV). B. In both TPH2-ChR2 and control mice, higher numbers of c-Fos positive 
neurons were observed ipsilateral to the pinch stimulus compared to the contralateral side. 
No significant difference was observed between control and stimulated animals, however a 
large variance in the number of c-Fos positive neurons was observed in both groups of 
animals. n=8 per group. **p<0.01 compared to contralateral side of the animals of the 
same genotype, Wilcoxon matched-pairs signed rank test. C. Transverse spinal cord 
section with lamina boundaries indicated. Black arrow indicates an incision made prior to 
sectioning to mark the contralateral side of the cord. Boxed areas indicate regions 
displayed at higher magnification in (D). D. Representative images of spinal cord sections 
from control and TPH2-ChR2-EYFP animals that displayed high or low counts of c-Fos 
positive dorsal horn neurons. 
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